WeTrials
Recruiting

Phase 2 Study of Avapritinib in Patients With CKIT or PDGFRA Mutation-Positive Malignant Solid Tumors

What is this study?

This study is testing a targeted medication called avapritinib to see if it can help patients with advanced solid tumors that have specific genetic changes called CKIT or PDGFRA mutations. The goal is to see if this medicine can block the signals that help cancer cells grow and spread.

Who can participate?

You may be able to join if you are 12 or older, have an advanced solid tumor that has not responded well to standard treatments, and your tumor has the specific genetic mutations this study is looking for. Certain conditions, like specific heart issues or having a gastrointestinal stromal tumor (GIST), mean you cannot join.

What will happen?

If you join, you will receive the study medication avapritinib, which is designed to block specific enzymes that cancer cells need to grow. Your health care team will closely monitor your health, how your body responds to the treatment, and any side effects you might experience.

Where and when?

This study is currently recruiting participants and takes place in Houston, Texas, United States. Your care team can help you find out if this location works for you.

Key Points
  • 1Testing a targeted cancer medicine called avapritinib
  • 2For patients with advanced solid tumors and specific genetic mutations
  • 3Currently recruiting participants in Houston, Texas

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Anatomic Stage IV Breast Cancer AJCC v8Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8Locally Advanced Malignant Solid NeoplasmLocally Advanced MelanomaLocally Advanced Primary Malignant Central Nervous System NeoplasmLocally Advanced SarcomaMetastatic Malignant Solid NeoplasmMetastatic MelanomaMetastatic Primary Malignant Central Nervous System NeoplasmMetastatic SarcomaPathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8Prognostic Stage IIIC Breast Cancer AJCC v8Prognostic Stage IV Breast Cancer AJCC v8Stage IIIC Colorectal Cancer AJCC v8Stage IIIC Lung Cancer AJCC v8Stage IV Colorectal Cancer AJCC v8Stage IV Lung Cancer AJCC v8Stage IVA Colorectal Cancer AJCC v8Stage IVA Lung Cancer AJCC v8Stage IVB Colorectal Cancer AJCC v8Stage IVB Lung Cancer AJCC v8Stage IVC Colorectal Cancer AJCC v8

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.